Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

• Introduction (0:00)
• Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
• Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)
• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)
• Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)

CME information and select publications

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.

CME information and select publications here.

Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.

CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.